CURCUMIN AND ITS EFFECT ON PREECLAMPSIA: AS ANTI-INFLAMMATORY, ANALGESIC, AND ANTICOAGULANT
Objective: Based on the Indonesia Health Profile In 2014, almost 30% of maternal deaths at Indonesia in 2010 were caused by hypertension in pregnancy, which one of them was preeclampsia. Many theories said to be the risk factor, such as acute body inflammation. Its clinical symptoms are hypertension, upper abdominal pain, and haemorrhage. Nowadays, many studies have been developed to predict the onset of preeclampsia, one of which is COX-2. This study was the first one to examine the benefits of curcumin in preeclamptic patients around the world.
This study aims to discover whether curcumin affects the level of COX-2, VAS, and anticoagulant factors in preeclamptic patients.
Methods: This is true experimental research with a double-blind randomized design. 50 samples were collected within a period of 7 mo and were divided into 2 groups: Case and Control Group. A total of 3 blood tests were conducted: prior, 90 min, and 12 h after case/treatment.
Results: 4 samples were eliminated during preparation. The total number of samples was 46; 23 in Control Group and 23 in Case Group. In this study, we found clinical changes in the level of COX-2, VAS and anticoagulant factors in patients given 100 mg of curcumin compared to those who were not. In addition, we also found a correlation between clotting time and bleeding time at T2 where both time factors became shorter.
Conclusion: There was a statistically significant decrease in COX-2 level in the Case Group, which led to decreased value of VAS, shorter clotting time and lower thrombocyte count; and, there was a significant correlation found between clotting time and bleeding time at T2 in the preeclamptic patients.
2. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res 2008;75:1–8.
3. Saraswati N, Mardiana. Faktor risiko yang berhubungan dengan kejadian preeklampsia pada Ibu Hamil (Studi Kasus di RSUD kabupaten brebes tahun 2014. Unnes J Public Health 2016;5:90-9.
4. Gupta Sc, Patchva S, Aggarwal Bb. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 2013;15:195–218.
5. Cheng SBD, Sharma S. Interleukin-10: a pleiotropic regulator in pregnancy. Am J Reprod Immunol 2015;73:487-500.
6. Anthwal A, Thakur BK, Rawat MSM, Rawat DS, Tyagi AK, Aggarwal BB. Synthesis, chara clotting timeerization and in vitro anticancer a clotting timeivity of C-5 curcumin analogues with potential to inhibit TNFa-induced NF-kB a clotting timeivation. Biomed Res Int 2014. Doi:10.1155/2014/524161
7. Kharaghanis R, Cheraghi Z, Esfahani BO, Mohammadian Z, Norreldinc RS. Prevalence of preeclampsia and eclampsia in Iran. Arch Iranian Med 2016;19:64-71.
8. Kim Y, Ryu M, Yang H. Increased sflt-1 to pigf ratio in women who subsequently develop preclampsia. J Korean Med Sci 2007;22:873–7.
9. Gupta Sc, Patchva S, Aggarwal Bb. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 2013;15:195–218.
10. Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, Dkk. Multitargeting by curcumin as revealed by molecular internal clotting timeion studies. Nat Prod Rep 2011;28:1937–55.
11. Julie SJ. Anti-inflammatory properties of curcumin, a major constituent of curcuma longa: a review of preclinical and clinical research. Alternative Med Rev 2009;14:141-53.
12. Nursal DGA, Tamela P, Fitrayeni. Faktor risiko kejadian preeklampsia pada ibu hamil di rsup. Dr. M. Djamil Padang Tahun. 2014, Jurnal Kesehatan Masyarakat Andalan; 2015.
13. Pratama MRF. Perbandingan afinitas kurkumin-enol dan kurkumin-keto terhadap COX-2, Universitas Muhammadiyah Palangkaraya; 2016.
14. Rao CV. Regulation of cox and lox by curcumin. The molecular targets and therapeutic uses of curcumin in health and disease; 2007. p. 213-26.
15. Milne B, Hall SR, Sullivan ME, Loomis C. The release of spinal prostaglandin E2 and the effeclotting time of nitric oxide synthetase inhibition during strychnine-induced allodynia. Anesth Analg 2001;93:728–33.
16. Jacob A, Wu R, Zhous M, Wang P. Mechanism of the anti-inflammatory effeclotting time of curcumin: Ppar-? AClotting Timeivation. Ppar Research; 2007.
17. Mihu D, Razvan C, Malutan A, Mihaela C. Evaluation of the maternal systemic inflammatory response in preeclampsia. Taiwanese J Obstetry Gynecol 2015;2:160–6.
18. Irawan H, Subagiartha I, Widnyana I. Pemberian magnesium sulfat intravena meningkatkan efek analgesia pascaoperasi pada bedah mayor menggunakan anestesi umum. Jurnal Anestesi Perioperatif FK Unpad; 2014.
19. Saha T, Halder M, Das A, Das SK. Role of nitric oxide, angiogenic growth faclotting timeors and biochemical analysis in preeclampsia. Indian J Biochem Biophys 2013;50:462-6.
20. Kahraman F, Eroglu A. The effeclotting time of intravenous magnesium sulfate infusion on sensory spinal block and postoperative pain score in abdominal hystereclotting timeomy. Biomed Res Int 2014. Doi:10.1155/2014/236024.
21. Zanjani TM, Ameli H, Labibi F, Sedaghat K, Sabetkasaei M. The attenuation of pain behaviour and serum COX-2 concentration by curcumin in a rat model of neuropathic pain. Korean J Pain 2014;27:246–52.
22. Zhang D, Chang X, Bai J, Chen Z, Li WP, Zhang C. The study of cyclooxygenase 2 in the human decidua of preeclampsia. Biol Reprod 2016;95:56.
23. Basnet P, Dan Skalko-Basnet N. Curcumin: An anti-in?ammatory molecule from a curry spice on the path to cancer treatment. Molecules 2011;16:4567–98.
24. Al-Safi Z, Imudia AN, Filetti LC, Hobson DT, Bahado Singh RO, Awonuga AO. Delayed postpartum preeclampsia and eclampsia. Obstet Gynecol 2011;118:1102–7.
25. Pan CJ, Tang JJ, Weng YJ, Wang J, Huang N. Preparation, characterization and anticoagulation of curcumin-eluting controlled biodegradable coating stents. J Controlled Release 2006;116:42-9.
26. Kim DC, Ku SK, Bae JS. Anticoagulant activities of curcumin and its derivative. BMB Reports 2012;45:221-6.
27. Martini N. Continuing professional development potion or poison? Turmeric. J Primary Health Care 2019;6:187-8.
This work is licensed under a Creative Commons Attribution 4.0 International License.